drugset / Trial / NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Phase 2
Completed
17 enrolled
University of Maryland, Baltimore
Gilead Sciences · collabUniversity of Miami Sylvester Comprehensive Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).
Timeline
- Start
- 2017-10-23
- Primary completion
- 2023-06-15
- Completion
- 2024-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idelalisib | Small molecule | 150 mg | Oral |